Skip to content
10-Q

Quarterly Report

Ventyx Biosciences, Inc.

0000950170-24-123485

← back to feed
Filed
Nov 7, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 4, 2024 70.71M sh
Current Liabilities Q3 2024 · Sep 30, 2024 $12.3M
Current Liabilities Q3 2024 · Dec 31, 2023 $22.27M
Total Liabilities Q3 2024 · Sep 30, 2024 $22.33M
Total Liabilities Q3 2024 · Dec 31, 2023 $33.77M
Current Assets Q3 2024 · Sep 30, 2024 $289.41M
Current Assets Q3 2024 · Dec 31, 2023 $264.35M
Total Assets Q3 2024 · Sep 30, 2024 $301.1M
Total Assets Q3 2024 · Dec 31, 2023 $277.69M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $51.58M
Cash And Equivalents Q3 2024 · Sep 30, 2023 $56.61M
Shares Diluted Q3 2024 · Sep 30, 2023 58.88M sh
Shares Diluted Q3 2024 · Sep 30, 2023 58.36M sh
Capex Q3 2024 · Sep 30, 2023 $303K
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$114.87M
Stockholders Equity Q3 2024 · Sep 30, 2023 $283.64M
Stockholders Equity Q3 2024 · Jun 30, 2023 $327.81M
Stockholders Equity Q3 2024 · Dec 31, 2022 $353.9M
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.92
Eps Diluted Q3 2024 · Sep 30, 2023 −$2.51
Eps Basic Q3 2024 · Sep 30, 2023 −$0.92
Eps Basic Q3 2024 · Sep 30, 2023 −$2.51
Sga Expense Q3 2024 · Sep 30, 2023 $8.2M
Sga Expense Q3 2024 · Sep 30, 2023 $23.9M
Rd Expense Q3 2024 · Sep 30, 2023 $49.75M
Rd Expense Q3 2024 · Sep 30, 2023 $133.75M
Net Income Q3 2024 · Sep 30, 2023 −$54.03M
Net Income Q3 2024 · Sep 30, 2023 −$146.21M
Operating Income Q3 2024 · Sep 30, 2023 −$57.95M
Operating Income Q3 2024 · Sep 30, 2023 −$157.65M